Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuvectis Pharma, Inc. (NASDAQ: NVCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Nuvectis files reports with the U.S. Securities and Exchange Commission, including Form 8-K current reports that describe material events such as quarterly financial results, corporate updates and board appointments.
In recent Form 8-K filings, Nuvectis has reported the release of press statements covering second and third quarter financial results, business highlights and progress in its oncology pipeline. These filings reference the company’s lead program NXP900, an oral small molecule inhibitor of the SRC Family of Kinases including SRC and YES1, and its clinical development from Phase 1a dose escalation through initiation of a Phase 1b program. They also discuss NXP800, an oral small molecule GCN2 activator with reported anti-cancer activity in recurrent, platinum-resistant, ARID1a-mutated ovarian cancer.
Filings confirm that Nuvectis’s common stock trades on the Nasdaq Capital Market under the symbol NVCT and that the company is classified as an emerging growth company. Additional 8-K reports document corporate governance developments, such as the appointment of a new member to the Board of Directors.
On Stock Titan, investors can use AI-powered tools to review Nuvectis’s SEC filings, with summaries that highlight key points from lengthy documents and clarify technical language. Real-time updates from EDGAR ensure that new 8-Ks, as well as other core filings like 10-K annual reports, 10-Q quarterly reports and Form 4 insider transaction disclosures when available, are quickly reflected. This structure helps users follow how clinical progress, financial performance and corporate decisions for NVCT are communicated through official regulatory channels.
Key take-away: Nuvectis Pharma, Inc. (NVCT) filed a Form 4 showing that 10% owner Charles Mosseri-Marlio, via Emerald Hill Ventures SARL SPF, bought 33,442 common shares in two open-market transactions on 17-18 Jun 2025.
- Prices: weighted-average $8.11 on 17 Jun for 5,399 shares and $8.05 (range $7.91-$8.11) on 18 Jun for 28,043 shares.
- Post-purchase holdings: 2,976,203 shares held indirectly, up from 2,942,761.
- Transaction code “P” confirms open-market purchases; no 10b5-1 plan indicated.
- No derivative securities or sales reported; filing does not include earnings or operational metrics.
The estimated cash outlay is roughly $270k; insider accumulation at market prices often signals management’s confidence and can be viewed as a bullish indicator by investors. Because the investor already owns more than 10% of NVCT, the additional purchase marginally increases an already significant stake and reinforces alignment with minority shareholders.